Detalles de la búsqueda
1.
Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.
Cancer
; 128(5): 966-974, 2022 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34784056
2.
FOLFOXIRI-Bevacizumab or FOLFOX-Panitumumab in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer: A Propensity Score-Based Analysis.
Oncologist
; 26(4): 302-309, 2021 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33336844
3.
A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.
Invest New Drugs
; 39(1): 163-174, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-32737717
4.
Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.
JAMA
; 325(13): 1277-1286, 2021 04 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-33821899
5.
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22-05): a single-arm, phase 1b-2 trial.
Lancet Oncol
; 21(8): 1066-1076, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32653053
6.
The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).
Oncologist
; 25(3): e451-e459, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32162804
7.
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.
Invest New Drugs
; 38(4): 1145-1155, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-31707688
8.
Phase I, First-in-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors.
Oncologist
; 24(4): 455-e121, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30478190
9.
First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors.
Invest New Drugs
; 37(1): 147-158, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30056611
10.
Integrated safety summary for trifluridine/tipiracil (TAS-102).
Anticancer Drugs
; 29(1): 89-96, 2018 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29176395
11.
A phase 1 dose-escalation and expansion study of binimetinib (MEK162), a potent and selective oral MEK1/2 inhibitor.
Br J Cancer
; 116(5): 575-583, 2017 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-28152546
12.
A Phase II Study with Lead-In Safety Cohort of 5-Fluorouracil, Oxaliplatin, and Lapatinib in Combination with Radiation Therapy as Neoadjuvant Treatment for Patients with Localized HER2-Positive Esophagogastric Adenocarcinomas.
Oncologist
; 22(10): 1152-e98, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28765502
13.
A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.
Oncologist
; 22(3): 264-271, 2017 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28209746
14.
A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial.
Oncologist
; 22(12): 1427-e129, 2017 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-28935773
15.
First-in-human study of the antibody DR5 agonist DS-8273a in patients with advanced solid tumors.
Invest New Drugs
; 35(3): 298-306, 2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28050790
16.
Phase Ib study of the mitochondrial inhibitor ME-344 plus topotecan in patients with previously treated, locally advanced or metastatic small cell lung, ovarian and cervical cancers.
Invest New Drugs
; 35(5): 627-633, 2017 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-28283779
17.
A Phase 2 Study of 5-Fluorouracil (5-FU), Ziv-Aflibercept, and Radiation for the Preoperative and Adjuvant Treatment of Patients with Stage II/III Rectal Cancer.
Cancer Invest
; 35(8): 535-540, 2017 Sep 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-28792245
18.
A Phase-2 Trial of Single Agent Axitinib as Maintenance Therapy Following First-Line Treatment With Modified FOLFOX/Bevacizumab in Patients With Metastatic Colorectal Cancer.
Cancer Invest
; 35(6): 386-392, 2017 Jul 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-28426267
19.
A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.
Int J Cancer
; 139(1): 177-86, 2016 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26891420
20.
A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection in Patients With Metastatic KRAS Wild-Type Colorectal Cancer With Liver Metastases Only.
Oncologist
; 21(3): 279-80, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26911408